New eczema drug shows promise in early trial
NCT ID NCT06094179
First seen Feb 17, 2026 · Last updated Jun 02, 2026 · Updated 18 times
Summary
This study tests a new drug called BAT6026 in adults with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard creams. The goal is to see if the drug is safe and can reduce skin symptoms like redness and itching. About 33 participants will receive different doses or a placebo to find the best dose for larger future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jianzhong Zhang
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.